Medrad signs UltraGuide

Article

Interventional CT represents a strategic opportunity for Medrad. The company has signed its second distribution agreement in three months, this one with Lakewood, CO-based UltraGuide, for products addressing this market segment.Medrad, a U.S. subsidiary

Interventional CT represents a strategic opportunity for Medrad. The company has signed its second distribution agreement in three months, this one with Lakewood, CO-based UltraGuide, for products addressing this market segment.

Medrad, a U.S. subsidiary of Schering, agreed in January to begin distributing UltraGuide's CT-Guide in the U.S. and France. The visual guidance system designed for minimally invasive CT procedures will be marketed along with SimpliCT, a CT guidance device manufactured by NeoRad. A distribution agreement for SimpliCT was signed in November. Interventional guidance is a natural extension of Medrad's product lines, according to the company, which provides MRI surface coils and power injectors for contrast-enhanced studies.

Recent Videos
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
A Closer Look at MRI-Guided Adaptive Radiotherapy for Monitoring and Treating Glioblastomas
Incorporating CT Colonography into Radiology Practice
What New Research Reveals About Computed Tomography and Radiation-Induced Cancer Risk
What New Interventional Radiology Research Reveals About Treatment for Breast Cancer Liver Metastases
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Related Content
© 2025 MJH Life Sciences

All rights reserved.